Secreted Virulence Proteins and biofilm formation in Candida
念珠菌分泌的毒力蛋白和生物膜的形成
基本信息
- 批准号:8598024
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-01-01 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:Antifungal AgentsAntifungal TherapyAreaAspartic EndopeptidasesAttenuatedBiochemicalBloodCandidaCandida albicansCandidiasisCaringCathetersDefectDiagnosisDisseminated candidiasisDrug TargetingExocytosisExtracellular SpaceFutureGenesGeneticGoalsGolgi ApparatusHealthcareHistopathologyHospitalsIn VitroInfectionInterventionLength of StayLipaseMaintenanceMediator of activation proteinMicrobial BiofilmsModelingMolecularMorbidity - disease rateMusMutationPathogenesisPathway interactionsPeptide HydrolasesPhenotypePhospholipasePopulationProteinsRoleSaccharomyces cerevisiaeSepsisSiteStagingStressSurvival AnalysisTetanus Helper PeptideTetracyclinesVacuolar Protein SortingVesicleVeteransVirulenceYeast Model Systemattributable mortalitycandida biofilmcandidemiacostdensityfungusin vivointerestkillingsmacrophagemortalitymouse modelmutantnovelnovel diagnosticspathogenpreventprotein complexprotein transportsecretory proteintrafficking
项目摘要
DESCRIPTION (provided by applicant):
The fungus Candida albicans has emerged as an important opportunistic nosocomial pathogen. Candida species are now the fourth most common cause of hospital-acquired bloodstream infections and are a major cause of morbidity and mortality in the veteran population. Despite improvements in antifungal therapy, the high attributable mortality rate due to Candida infections is no better than two decades ago, and diagnostically, the traditional blood culture has only a 50% sensitivity to detect invasive candidiasis. Thus, our ability to prevent, diagnose, and treat Candida infections is still in need of great improvement. In the effort to identify novel diagnostic and drug targets, a number of C. albicans virulence-associated proteins have been investigated, and many of these are secretory proteins such as the secreted aspartyl proteases (Saps) and phospholipases. In addition, considerable recent effort has been made to study Candida biofilms, another key component of Candida pathogenesis. These biofilms enable Candida to colonize a protected site from which dissemination of infection and protection from anti-fungal therapy can occur. Thus, our overall objectives are to: (i) determine which genes are critical for the trafficking and secretion of Saps and other virulence proteins, and (ii) define the role of secretion in biofilm formation. If we can identify these key genes, this information may prove invaluable for understanding the mechanisms of biofilm formation and for identifying novel drug targets. In previous studies, we examined the role of the pre-vacuolar secretory pathway in the secretion of virulence-associated proteins and biofilm formation in C. albicans, regulated by the vacuolar protein sorting genes VPS1, VPS4, and PEP12. Of great interest, a C. albicans pep12 mutant was defective in virulence in vivo, and formed a biofilm that dramatically fragmented with minimal disturbance. Expanding on these studies, we will examine the late stages of secretion by examining key final steps in exocytosis regulated by the Exocyst protein complex, and determine its contribution to biofilm formation and virulence. Next, we will examine the molecular mechanisms of biofilm formation by investigating the critical determinants of biofilm integrity in the pep12 mutant. Therefore, this project will examine the key hypotheses that: (i) C. albicans exocytosis mutants missort proteins to the extracellular space resulting in defective biofilm formation, and (ii) mutations in secretory pathway genes at key steps in exocytosis will result in attenuated virulence in vivo, and (iii) C. albicans PEP12 is a key mediator of biofilm integrity. Specific Aim 1 is to determine the effects of mutations in C. albicans exocytosis genes at key steps of polarized secretion and their contribution to biofilm formation. Specific Aim 2 is to directly examine the requirement of C. albicans exocytosis genes for virulence in vitro and in vivo. Specific Aim 3 is to determine whether downstream effectors of C. albicans PEP12 are required for maintenance of biofilm integrity. Thus, our overall objectives are to define the key trafficking genes and pathways of these important secreted virulence proteins, and define their role in biofilm formation in order to understand mechanisms of pathogenesis and identify novel drug targets.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SAMUEL AUSTIN LEE其他文献
SAMUEL AUSTIN LEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SAMUEL AUSTIN LEE', 18)}}的其他基金
Endocytosis in Candida filamentation, biofilm formation and virulence
念珠菌丝状形成、生物膜形成和毒力中的内吞作用
- 批准号:
10266031 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Secreted Virulence Proteins and biofilm formation in Candida
念珠菌分泌的毒力蛋白和生物膜的形成
- 批准号:
8392105 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Secreted Virulence Proteins and biofilm formation in Candida
念珠菌分泌的毒力蛋白和生物膜的形成
- 批准号:
8141795 - 财政年份:2012
- 资助金额:
-- - 项目类别:
相似海外基金
Mitophagy as a target for antifungal therapy
线粒体自噬作为抗真菌治疗的靶点
- 批准号:
488010 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection
加强抗真菌治疗可提高早期播散性隐球菌感染的生存率
- 批准号:
10621009 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial
儿童念珠菌血症的短期疗程与标准疗程抗真菌治疗:多中心随机对照试验
- 批准号:
10677753 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial
儿童念珠菌血症的短期疗程与标准疗程抗真菌治疗:一项多中心随机对照试验
- 批准号:
10487627 - 财政年份:2022
- 资助金额:
-- - 项目类别:
(1-3)-beta-D-glucan guided early termination of antifungal therapy in ICU patients
(1-3)-β-D-葡聚糖指导 ICU 患者提前终止抗真菌治疗
- 批准号:
400727961 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Research Grants
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons
对无症状 CRAG 阳性者进行强化抗真菌治疗的 CRAG 筛查评估
- 批准号:
10341089 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Directed Antifungal Therapy for HIV-associated Cryptococcal Meningitis
HIV 相关隐球菌性脑膜炎的定向抗真菌治疗
- 批准号:
8991829 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Targeting hybrid histidine kinase for broad spectrum antifungal therapy
靶向混合组氨酸激酶进行广谱抗真菌治疗
- 批准号:
7936212 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Targeting hybrid histidine kinase for broad spectrum antifungal therapy
靶向混合组氨酸激酶进行广谱抗真菌治疗
- 批准号:
7812372 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Optimizing antifungal therapy for HIV-associated cryptococcal meningitis in Africa
优化非洲艾滋病毒相关隐球菌性脑膜炎的抗真菌治疗
- 批准号:
G0501476/1 - 财政年份:2006
- 资助金额:
-- - 项目类别:
Research Grant